In some welcome good news, "The European Commission has approved a fixed-dose combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL)"
onclive.com/web-exclusives/...
Neil